Metformin Plus Irinotecan for Refractory Colorectal Cancer
MetIri seeks to identify if metformin combined to irinotecan can improve tumor control.
Colorectal Neoplasms|Adenocarcinoma
DRUG: metformin|DRUG: irinotecan
Non-Progression at week 12th of treatment, Non-Progression at week 12th of treatment, 12th week
Progression-free survival, Progression-free survival, 12th week|Overall Survival, Overall Survival, 12th week|Quality of life, Measured by EORTC QLQ C30, 12th week|Safety, Assessment of toxicity according to CTC 4.0, 12th week
MetIri is a two-stage single arm Phase II assessing the role of combination of metformin to irinotecan for colorectal cancer patients already treat with oxaliplatin, fluoropyrimidine, irinotecan and an anti-EGFr antibody if KRAS wild-type.